Trials / Terminated
TerminatedNCT02483533
Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202
A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Evofem Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
LIPO-202-CL-23 is a follow-on study to evaluate the post-treatment safety and duration of clinical effect of LIPO-202 in subjects that completed either the LIPO-202-CL-18 (NCT02397499) or LIPO-202-CL-19 (NCT02398188). No risks related to treatment are anticipated as subjects will not receive additional treatment with LIPO-202 or Placebo for LIPO-202 in this follow-on study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LIPO-202 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2015-12-23
- Completion
- 2016-02-26
- First posted
- 2015-06-29
- Last updated
- 2019-12-10
- Results posted
- 2019-12-10
Source: ClinicalTrials.gov record NCT02483533. Inclusion in this directory is not an endorsement.